☆ 4.7 Editorial Material

Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use

EUROPEAN HEART JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Letter Cardiac & Cardiovascular Systems

Comparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model

Samuel C. R. Sherratt et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Add to Collection

Review Peripheral Vascular Disease

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

Samuel C. R. Sherratt et al.

Summary: This review examines the effects of omega-3 fatty acids (n3-FAs) on cardiovascular risk reduction. It has been found that high-purity EPA ethyl ester has significant benefits in reducing cardiovascular events and atherosclerosis progression compared to mixed EPA/DHA treatments. Mechanistic differences between n3-FAs, including membrane interactions, metabolic products, cholesterol efflux, antioxidant properties, and tissue distribution, have been explored.

CURRENT ATHEROSCLEROSIS REPORTS (2023)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment

William S. Weintraub et al.

Summary: The study demonstrates the cost-effectiveness of Icosapent ethyl compared with standard care for high-risk patients with hypertriglyceridemia. Treatment with IPE yields more quality-adjusted life-years (QALYs) and better cardiovascular outcomes than standard care both in-trial and over a lifetime projection.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Pharmacology & Pharmacy

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Prakriti Gaba et al.

Summary: This article reviews the key findings of the REDUCE-IT trial and its subsequent analyses, highlighting the efficacy of IPE in high-risk cardiovascular patients, and calls for its inclusion in current guidelines.

JOURNAL OF CLINICAL LIPIDOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results

Matthew J. Budoff et al.

Summary: This study aims to evaluate the effects of IPE as an adjunct to statin therapy on atherosclerotic plaque characteristics in high-risk cardiovascular patients with persistently high triglyceride levels. The interim analysis at 9 months showed that while there was no significant change in low attenuation plaque, there was a slowing of total non-calcified plaque, total plaque, fibrous plaque, and calcified plaque in the IPE group compared to placebo.

CARDIOVASCULAR RESEARCH (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl

Gabriel Steg et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs

Takahito Doi et al.

Summary: This study compared the effects of active and comparator oils on lipid traits and C-reactive protein in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) and Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridaemia (STRENGTH). The results suggest that the difference in the risk reduction between REDUCE-IT and STRENGTH may be partly explained by the difference in the effects of comparator oils (mineral vs. corn) on lipid traits and C-reactive protein, rather than the active oils.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Letter Medicine, General & Internal

Meta-Analysis of Contemporary Trials of Omega-3 Fatty Acids Containing Both Eicosapentaenoic and Docosahexaenoic Acids

Safi U. Khan et al.

ECLINICALMEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs

Takahito Doi et al.

Summary: This study analyzed data from two randomized trials and found that the differing results in the effect of high-dose, purified omega-3 fatty acids on the prevention of ASCVD in REDUCE-IT and STRENGTH trials may be partly explained by differences in the effect of comparator oils, but not active oils, on lipid traits and C-reactive protein. The unexplained additional 13% risk reduction in REDUCE-IT may be due to other effects of EPA or mineral oil.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Clinical review on triglycerides

Ulrich Laufs et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography

Suvasini Lakshmanan et al.

CARDIOVASCULAR RESEARCH (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics

William E. Boden et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Review Medicine, General & Internal

Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk

Dave L. Dixon

AMERICAN JOURNAL OF MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

Matthew J. Budoff et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

Brian Olshansky et al.

EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis

Mitsuhiro Yokoyama et al.

LANCET (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.